Vontobel Holding
ACRS icon

Vontobel Holding’s Aclaris Therapeutics ACRS Stock Holding History

Vontobel Holding’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$93.8K Sell
25,000
-1,000
-4% -$3.37K ﹤0.01% 1152
2025
Q4 		$78.3K Hold
26,000
– – ﹤0.01% 1381
2025
Q3 		$49.4K Hold
26,000
– – ﹤0.01% 1325
2025
Q2 		$36.9K Buy
26,000
+4,000
+18% +$5.41K ﹤0.01% 1246
2025
Q1 		$33.7K Buy
22,000
+6,000
+38% +$12.8K ﹤0.01% 1077
2024
Q4 		$39.7K Sell
16,000
-4,000
-20% -$9.95K ﹤0.01% 1083
2024
Q3 		$23K Hold
20,000
– – ﹤0.01% 1071
2024
Q2 		$22K Hold
20,000
– – ﹤0.01% 1060
2024
Q1 		$24.8K Sell
20,000
-10,268
-34% -$12.2K ﹤0.01% 1070
2023
Q4 		$31.8K Buy
30,268
+17,040
+129% +$52K ﹤0.01% 1083
2023
Q3 		$90.6K Sell
13,228
-1,000
-7% -$8.54K ﹤0.01% 1024
2023
Q2 		$148K Hold
14,228
– – ﹤0.01% 1029
2023
Q1 		$115K Buy
+14,228
New +$181K ﹤0.01% 1022

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vontobel Holding's ACRS Position: Q1 2026 in Review

Vontobel Holding reduced its Aclaris Therapeutics (ACRS) stake by 3.8% in Q1 2026, selling an estimated $3.37K and leaving 25,000 shares worth $93.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1152.

Vontobel Holding first reported a position in ACRS in Q1 2023 and has held it in 13 quarters since. The position peaked at $148K in Q2 2023. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Vontobel Holding held 25,000 shares of Aclaris Therapeutics worth $93.8K as of Q1 2026.
  • Vontobel Holding sold 1,000 Aclaris Therapeutics shares in Q1 2026, an estimated $3.37K.
  • Aclaris Therapeutics made up ﹤0.01% of Vontobel Holding's portfolio in Q1 2026, its #1152 holding.
  • Vontobel Holding first reported a position in Aclaris Therapeutics in Q1 2023 and has held it in 13 quarters since.
  • Vontobel Holding's Aclaris Therapeutics position peaked at $148K in Q2 2023.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Vontobel Holding's 13F filing for Q1 2026, filed 8 May 2026.